Palvella Therapeutics financials
$139.00−0.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$21.4M | -$14.9M | -$11.3M | -$10.2M | -$9.3M | -$7.9M | -$4.4M |
| Net income | -$21.9M | -$15.8M | -$12.7M | -$11.3M | -$9.5M | -$8.2M | -$3.4M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-1.52 | $-1.20 | $-1.07 | $-1.03 | $-0.86 | $-0.74 | $-0.94 |
| EBITDA | -$21.4M | -$14.9M | -$11.3M | -$10.2M | -$9.3M | -$7.9M | -$4.4M |
| Operating cash flow | -$12.8M | -$10.9M | -$4.9M | -$7.9M | -$5.4M | -$6.8M | -$5.4M |
| Free cash flow | -$12.8M | -$10.9M | -$4.9M | -$7.9M | -$5.4M | -$6.8M | -$5.4M |
| Diluted shares | 14.4M | 13.1M | 11.9M | 11.1M | 11.1M | 11.0M | 3.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $187.8M | $206.4M | $58.0M | $63.6M | $70.4M | $75.6M |
| Short-term investments | $62.8M | $55.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $253.5M | $263.8M | $59.6M | $66.9M | $73.7M | $79.4M |
| Total liabilities | $36.6M | $31.4M | $31.6M | $28.3M | $26.0M | $23.9M |
| Shareholders' equity | $216.9M | $232.3M | $28.0M | $38.7M | $47.8M | $55.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology